APA (7th ed.) Citation

T, Z., MR, H., PH, O., AS, A., NM, H., LJ, A., . . . DJ, G. (2020). A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer, 126(20), 4485. https://doi.org/10.1002/cncr.33067

Chicago Style (17th ed.) Citation

T, Zhang, et al. "A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients with Platinum-resistant Metastatic Urothelial Cancer." Cancer 126, no. 20 (2020): 4485. https://doi.org/10.1002/cncr.33067.

MLA (9th ed.) Citation

T, Zhang, et al. "A Randomized Phase 2 Trial of Pembrolizumab Versus Pembrolizumab and Acalabrutinib in Patients with Platinum-resistant Metastatic Urothelial Cancer." Cancer, vol. 126, no. 20, 2020, p. 4485, https://doi.org/10.1002/cncr.33067.